Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

150.21 -2.02 (-1.33%)

Streaming Delayed Price Updated: 3:15 PM EDT, Jul 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Biotech Stocks And The SVB Collapse — Here's What We Know ↗

March 14, 2023

The collapse of SVB will have a big impact on early-stage, venture-backed companies.

Via Investor's Business Daily

Silicon Valley Bank Meltdown Hits Healthcare Sector As Well ↗

March 13, 2023

The Federal Deposit Insurance Corporation (FDIC) closed Silicon Valley Bank, the banking arm of SVB Financial Group (NASDAQ:

Via Benzinga

Small Cap Biotechs Slammed By SVB Collapse ↗

March 13, 2023

Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation.

Via Talk Markets

6 Stock Market Thoughts For The Week Of March 13 ↗

March 12, 2023

A flight to safety seemed to be at play this week, with the market seeking safety first and asking questions later. This is not unusual, and once the situation is resolved, much of the decline in rates...

Via Talk Markets

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗

March 10, 2023

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...

Via Benzinga

FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities ↗

March 10, 2023

Via Benzinga

Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading ↗

March 06, 2023

Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.

Via Talk Markets

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades' ↗

January 31, 2023

On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the SPDR S&P Biotech ETF (NYSE: XBI), saying if you "want growth,

Via Benzinga

Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January ↗

January 30, 2023

Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.

Via Talk Markets

2 ETFs That Can Set You Up for Life ↗

January 25, 2023

Simplifying your investment strategy can help minimize your risk while still allowing you to earn some great returns.

Via The Motley Fool

Healthcare Sector Is Lagging As We Enter 2022 Earnings Season ↗

January 23, 2023

The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength.

Via Talk Markets

The Fed Should Stop Right Now ↗

January 19, 2023

A pause to refresh or a mild pullback would be good for the stock market after running hot and heavy. On Wednesday, we saw weaker economic data in retail sales. Unlike previous soft data, the stock...

Via Talk Markets

J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps ↗

January 17, 2023

Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing.

Via Talk Markets

Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing” ↗

January 12, 2023

Small-cap speculative biotech stocks regain interest with volatility.

Via Talk Markets

3 Unstoppable ETFs to Stock Up On in 2023 ↗

January 09, 2023

These ETFs could be big winners in the new year.

Via The Motley Fool

ETFs To Buy For 2023 After S&P 500's Worst Year Since 2008 ↗

January 08, 2023

The S&P 500 has dropped 19.4% in 2022. It marked the largest calendar-year decline since a 38% plunge in Lehman Bother’s crisis-laden 2008. Goldman Sachs, Bank of America and JPMorgan predict a U.S....

Via Talk Markets

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

5 Top Stocks for January ↗

January 01, 2023

Now is the time to begin crafting your watch list for 2023.

Via The Motley Fool

The Year In Review And Ahead ↗

December 29, 2022

We‘ll continue witnessing cost-push inflation combined with tight labor market – and it would be crude oil‘s time again to gain in value from current levels.

Via Talk Markets

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

2 Top Biotech Stocks to Buy for the Long Haul ↗

December 25, 2022

These mid-cap biotechs are solid long-term choices.

Via The Motley Fool

Tuesday Talk: Where is Santa? ↗

December 20, 2022

Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.

Via Talk Markets

Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro ↗

December 19, 2022

The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.

Via Talk Markets

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond ↗

December 18, 2022

Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year.

Via InvestorPlace

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead ↗

November 28, 2022

Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.

Via Talk Markets

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

State Street SPDR S&P Biotech ETF (NY:XBI)

All News about State Street SPDR S&P Biotech ETF

Starting at /week.